Monthly Archives: February 2017

///February

Pharma Two B raises $30M for Parkinson’s phase 3 from Biogen-backed fund, adds ex-Pfizer CEO to board

by Nick Paul Taylor | Feb 27, 2017 7:34am Pharma Two B will run a phase 3 of its pramipexole-rasagiline fixed-dose combination P2B001. Pharma Two B has raised $30 million (€28 million) to complete a phase 3 trial of its Parkinson’s asset P2B001. The round provides a hint of the impact of the recently founded [...]

By |2018-11-20T08:54:48+00:00February 28th, 2017|Blog|Comments Off on Pharma Two B raises $30M for Parkinson’s phase 3 from Biogen-backed fund, adds ex-Pfizer CEO to board

7 disruptive innovations from medical device suppliers

Medical device innovation doesn’t just come from small, single-product startups – contract manufacturers are increasingly a part of developing truly disruptive medtech.  Chris Newmarker, Managing Editor   People sometimes make the mistake of viewing innovation as the product of a few geniuses and mavericks. But in fact, it is often the result of teamwork, as the [...]

By |2018-11-20T08:55:03+00:00February 28th, 2017|Blog|Comments Off on 7 disruptive innovations from medical device suppliers

Medtech Insight’s weekly podcast on Biomed Israel and Israeli medical devices & digital health companies

Listen to Medtech Insight's podcast on selected Israeli medical device & digital health companies that was broadcast this week. On this week's Medtech Insight podcast: the response by a US FDA advisory panel to Claret Medical's de novo submission for the first brain-filter device intended to protect patients undergoing transcatheter aortic heart valve replacement; a [...]

By |2018-11-20T08:55:10+00:00February 27th, 2017|Blog|Comments Off on Medtech Insight’s weekly podcast on Biomed Israel and Israeli medical devices & digital health companies

Genetically engineered T-cells treat leukemia in babies

Genetically engineered T-cells treat leukemia in babies February 16, 2017 By Danielle Kirsh Researchers in London have successfully treated leukemia in two babies, in what they are touting as the world’s first treatment of cancer using genetically engineered immune cells from donors.Doctors treated two British infants, 11 and 16 months old, using Cellectis’s CAR T-cell [...]

By |2018-11-20T08:55:21+00:00February 27th, 2017|Blog|Comments Off on Genetically engineered T-cells treat leukemia in babies

MindUP incubator takes in first startup

Hemonitor measures blood flow in the main artery of intensive care patients. The MindUP technology incubator, a partnership between Pitango Venture Capital, the Rambam Health Care Campus, medical device company Medtronic, IBM, and the Impact First investment fund, has accepted its first company - Hemonitor.Hemonitor measures blood flow in the main artery of patients arriving [...]

By |2018-11-20T08:55:36+00:00February 27th, 2017|Blog|Comments Off on MindUP incubator takes in first startup

Intensix Data Analytics Demo High Accuracy In ICU Sepsis Detection

Catherine Longworth@MedtechCate catherine.longworth@informa.com Executive Summary An analytics platform developed by Israeli big data company Intensix has shown high accuracy for detecting and predicting sepsis in critical care. The positive results were presented at the Healthcare Information and Management Systems Society (HIMSS) healthcare IT conference in Orlando, Florida. A new study has shown that an analytics [...]

By |2018-11-20T08:55:48+00:00February 27th, 2017|Blog|Comments Off on Intensix Data Analytics Demo High Accuracy In ICU Sepsis Detection

BrainStorm seeks early approval for stem cell treatment in Canada

Israel's BrainStorm Cell Therapeutics is seeking early approval in Canada for its adult stem cell treatment for patients with amyotrophic lateral sclerosis (ALS), a neuro-degenerative disease, even before it completes late-stage clinical trials. BrainStorm said on Tuesday that it had signed an agreement with CCRM, a Canadian not-for-profit organization that supports development of regenerative medicine, [...]

By |2018-11-20T08:55:55+00:00February 26th, 2017|Blog|Comments Off on BrainStorm seeks early approval for stem cell treatment in Canada

Why US corporate giants like Intel need fresh Israeli tech

Mammoth American multinationals depend on ingenuity from small Israeli startups to drive their businesses forward. By Abigail Klein Leichman FEBRUARY 20, 2017, 10:20 AM To understand the strong and rising impact of Israeli startups on the US tech scene, consider this month’s Super Bowl LI. Intel and FOX Sports unveiled a 360-degree “Be the Player” [...]

By |2018-11-20T08:56:10+00:00February 26th, 2017|Blog|Comments Off on Why US corporate giants like Intel need fresh Israeli tech

VBL posts additional data from phase 2 thyroid cancer trial

by Nick Paul Taylor | Feb 21, 2017 9:45am VBL Therapeutics has presented more data from a phase 2 trial of VB-111 monotherapy in thyroid cancer patients. The release adds evidence of dose response to support the previously reported difference in progression-free survival between the low- and high-dose cohorts. Tel Aviv, Israel-based VBL presented top-line [...]

By |2018-11-20T08:56:44+00:00February 23rd, 2017|Blog|Comments Off on VBL posts additional data from phase 2 thyroid cancer trial

Day Two link with Johnson & Johnson on personalised microbiome analysis for diabetes nutrition

By Eliot Beer, 15-Feb-2017 Gut microbiome analysis firm DaylWo will collaborate with Johnson & Johnson on personalised clinical nutrition for diabetes, and plans to open up its nutrition recommendation platform to new partners. DayTwo, based in Israel, currently offers a personalised nutrition recommendation product, based on a user's medical history and gut microbiome analysis. Users [...]

By |2018-11-20T08:56:54+00:00February 23rd, 2017|Blog|Comments Off on Day Two link with Johnson & Johnson on personalised microbiome analysis for diabetes nutrition